London, United Kingdom
CircaGene, founded in 2018 and headquartered in the United Kingdom, is pioneering advancements in personalized healthcare through its state-of-the-art bioinformatics services. The company, operating primarily within the Health Care, Health and Wellness, and Clean Energy industries, is dedicated to safeguarding public health on both population and individual levels.
The company's flagship offering is the CircaGene platform for personal genetic tests, which boasts the world's first patented Incognito DNA Encryption with actionable results. This innovation underscores their commitment to privacy and efficacy, addressing key consumer concerns in genetic testing.
Backed by a £187.52K Pre Seed Round investment from SFC Capital in April 2020, CircaGene is strategically positioned for growth. Its technologically sophisticated approach and focus on genetic data protection present promising prospects for investors seeking opportunities at the intersect of health and tech innovations.
